Designed for consumers with trouble sleeping, Grön’s Tart Cherry Pearls come in a 10:1 (TruCBN:THC) ratio, with most of the focus being on the sedative properties in the cannabinoid CBN.

In a study done by Radicle Science in collaboration with FloraWorks, researchers sought to scientifically explore and verify the efficacy of TruCBN, a proprietary CBN product developed by FloraWorks as a sleep aid. More than 1,000 volunteers from the U.S., each experiencing difficulties with sleep, participated in the study. The study found that participants who took 25, 50, and 100 mg of TruCBN all showed a significant improvement in sleep compared to placebo groups, with 50 mg of TruCBN having the greatest clinically meaningful improvement in their sleep out of any groups, including the melatonin group. The study also found that there were no significant side effects between any dose of TruCBN compared to the placebo group.

“Grön is ushering in a new era in the cannabis edibles market with the launch of their Tart Cherry Pearls,” said FloraWorks CEO Allen Lindquist. “This is one of the first products to contain FloraWorks TruCBN, which has been clinically validated to improve sleep quality. This product marks a significant milestone, setting a new standard for customer confidence in the adult-use cannabis market.”

Tart Cherry Pearls produce a calming and relaxing effect. Each pearl contains 2.5 mg THC (25 mg per package) and 25 mg of TruCBN (250 mg per package).

“We believe in exploring the effects of minor cannabinoids and infusing them into our products to take advantage of the functional properties of the cannabis plant,” said Christine Smith, CEO and founder of Grön. “While THC and CBD are the most common, the plant can offer us so much more, and we want to provide those properties to our customers. We’re very excited about the science-backed research on FloraWorks’ TruCBN and are proud to be able to add Tart Cherry to our product line.”